{
    "nctId": "NCT01205334",
    "officialTitle": "Phase I/II Administration of CMV (Cytomegalovirus)-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)",
    "inclusionCriteria": "* Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).\n* CMV-positive GBM\n* CMV seropositive\n* Life expectancy 6 weeks or greater\n* Karnofsky/Lansky score 50 or greater\n* Patient or parent/guardian capable of providing informed consent\n* Bilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater\n* Pulse oximetry of 90% or greater on room air\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom.\n* Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.\n* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.",
    "exclusionCriteria": "* Severe intercurrent infection\n* Known HIV positivity\n* Pregnant or lactating\n* History of hypersensitivity reactions to murine protein-containing products."
}